Press Room

Press Release / Sep 13, 2009

Hovione Appoints Terry Lambe to its Board of Directors

Cork, 10th September 2009 – Hovione announced today that Terry Lambe, Ph.D., has been elected to the Board of Directors of Hovione Ltd.

Hovione acquired earlier this year an important API manufacturing site located in Cork. This is a key element of the Hovione strategy to become a leading manufacturer to the pharmaceutical industry.

“We are delighted to welcome Terry Lambe to Hovione. We want to build our Cork site into the ideal, preferred, launch facility for new product introductions. In the context of the emerging business model based on outsourcing, our Cork site provides innovator pharmaceutical companies with all the benefits of a top manufacturing facility without the costs of ownership. Terry has a good understanding of what Large Pharma requires and brings to Hovione a wealth of international experience in manufacturing activities. We also feel that to do this right it is important to have on the board of our subsidiary company in Ireland someone familiar with the local culture and with strong links into the Irish pharmachem industry” said Guy Villax, Hovione’s Chief Executive. In addition Terry also becomes a member of the Hovione Manufacturing Committee that sets out the longer-term production strategy for the group.

“I am enthusiastic about joining a successful and dynamic company like Hovione and I hope to be able to make a significant contribution to its profitable growth”, said Dr. Lambe.

Dr. Terry Lambe joins Hovione following his retirement from Pfizer Inc. in 2008. Dr. Lambe worked at Pfizer for 30 years, during this time he held roles of increasing responsibility in manufacturing and was responsible for the construction of several API facilities, in Puerto Rico, in Groton, Connecticut and later in Singapore. In 1999, Dr. Lambe assumed his role as Vice President, Global Drug Substance. In 2000, he was appointed Team Leader / Vice President, Ireland / Singapore Manufacturing Area, a position he held until 2008. In 2004, Dr. Lambe was awarded the Bio-Link USA - Ireland Life Science Award for his contribution to the Pharmaceutical Industry. He holds a B.S. and a Ph.D. in Chemistry from University College Cork and completed a post-doctoral fellowship in Electro-Fluorination Chemistry at the University of Manchester.

About Hovione

Hovione is an international company with 50 years’ experience in active pharmaceutical ingredient development and compliant manufacture. With four FDA inspected sites in the US, China, Ireland and Portugal the company focuses on the most demanding customers in the most highly regulated markets. The company also offers integrated API, particle design and formulation development and manufacturing. In the inhalation area Hovione is the only independent company offering such a broad range of services.

For further information about Hovione, please visit the Hovione site at www.hovione.com or contact Corporate Communications (Isabel Pina, + 351 21 982 9362, e-mail: hello@hovione.com)

 

 

Also in the Press Room

See All

Continuous Tableting (CT) is defined as continuous manufacturing of oral dose drugs, specifically tablets. As per ICH's Q13 definition1, a continuous manufacturing process in the pharmaceutical industry comprises at least two unit operations integrated from a mechanical and software perspective. There is a wide combination of possible CT process configurations that are dependent on the needs of the intended product formulation and each of the individual unit operations that constitute the process train can be continuous, semi-continuous, or batch processes. The typical manufacturing processes for tablet formulation are direct compression (DC), dry granulation (DG) and wet granulation (WG)2 - details on these manufacturing processes are beyond the scope of this article, so the interested reader is directed to relevant literature. The actual implementation of CT technology in a facility can broadly vary depending on the level of desired integration and automation. Process trains can be designed to be flexible and converted between multiple configurations (e.g. continuous DC, DG and WG), controlled by the end user from one single software and within a single clean room. The other possibility would be for subsections of the CT process to be divided into multiple clean rooms where inprocess materials are transferred between suites via a bin-to-bin approach (e.g. a granulation suite to prepare granules from raw materials followed by continuous DC (CDC) to blend the granules and produce tablets). The level of automation and instrumentation designed into the CT process (typically involving Process Analytical Technologies, PAT) can open the possibility to implement sophisticated control strategies. Key components of a control strategy that need to be considered for CT are material tracking and genealogy, knowledge of the residence time distribution (RTD), and in-process controls (spectroscopic and/or soft sensors based on process parameters). Holistically, these control strategy elements enable the implementation of a material diversion strategy to automatically divert out of specification material from the process. In their most advanced form, control strategies may also enable real time release testing (RTRt) of the final tablet drug product and reduce the off-line analytical burden and the number of operators needed to manage the process.   Read the full article at gmp-journal.com  

Article

Continuous Tableting and the Road to Global Adoption

Mar 04, 2024